290 related articles for article (PubMed ID: 34737636)
1. Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy.
Feng QZ; Chen XZ; Sun J; Lu MM; Wang Y; Wang Q; Zhang C
Cancer Manag Res; 2021; 13():8077-8084. PubMed ID: 34737636
[TBL] [Abstract][Full Text] [Related]
2. Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients.
Wu D; Xiong L
Oncol Lett; 2020 Mar; 19(3):2539-2546. PubMed ID: 32194757
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.
Han L; Kuang L
J BUON; 2019; 24(4):1544-1548. PubMed ID: 31646806
[TBL] [Abstract][Full Text] [Related]
4. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
[TBL] [Abstract][Full Text] [Related]
5. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
Zhang J; Wei Q; Dong D; Ren L
Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
7. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
8. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER-2 positive breast cancer patients.
Tehrani SS; Zaboli E; Sadeghi F; Khafri S; Karimian A; Rafie M; Parsian H
Biomedicine (Taipei); 2021; 11(2):30-39. PubMed ID: 35223402
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H; Yu D; Wang J; Qiu T; Yang J; Wang L
Anticancer Drugs; 2008 Mar; 19(3):317-23. PubMed ID: 18510179
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Significance of CA15-3 with Combination of HER-2/neu Values at 85th Percentiles in Breast Cancer.
Thriveni K; Deshmane V; Ramaswamy G; Krishnamoorthy L
Indian J Clin Biochem; 2013 Apr; 28(2):136-40. PubMed ID: 24426198
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
13. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
14. Clinical Effects of Chinese Herbal Decoction Combined with Basic Chemoradiotherapy and Nursing Intervention in the Treatment of Cervical Cancer and the Effect on Serum CEA, CA125, and TNF-
Gao L; Lv J; Hou L; Yuan Y; Wan Q
Evid Based Complement Alternat Med; 2021; 2021():1446864. PubMed ID: 34603461
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer].
Xu L; Ye JM; Zhu SN; Zhao JY; Xin L; Cheng YJ; Liu Q; Zhang H; Zhang S; Duan XN; Liu YH
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):907-911. PubMed ID: 29665663
[No Abstract] [Full Text] [Related]
16. Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer.
Lin H; Chang J; Li J
Iran J Public Health; 2020 Oct; 49(10):1885-1893. PubMed ID: 33346209
[TBL] [Abstract][Full Text] [Related]
17. Conventional Tumor Markers in Cerebralspinal Fluid in Patients with Elevated Serum Tumor Markers and without Central Nervous System Malignant Diseases.
Liu ZJ; Shi Q; Lu B; Zhang Z; Tian CL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):539-542. PubMed ID: 27825410
[TBL] [Abstract][Full Text] [Related]
18. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Kontani K; Kuroda N; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Kushida Y; Date M; Haba R; Houchi H; Yamauchi A; Yokomise H
Cancer Biol Ther; 2013 Jan; 14(1):20-8. PubMed ID: 23114645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
